Home » Transgene Sells Option on Cancer Vaccine to Novartis
Transgene Sells Option on Cancer Vaccine to Novartis
Transgene SA, the French biotechnology company backed by the billionaire Merieux
family, sold Novartis AG an option on rights to the experimental TG4010 cancer vaccine in a deal that may fetch as much as $960 million.
BusinessWeek
BusinessWeek
Upcoming Events
-
07May
-
14May
-
30May